Structural determinants for subnanomolar inhibition of the secreted aspartic protease Sapp1p from Candida parapsilosis

J Enzyme Inhib Med Chem. 2021 Dec;36(1):914-921. doi: 10.1080/14756366.2021.1906664.

Abstract

Pathogenic Candida albicans yeasts frequently cause infections in hospitals. Antifungal drugs lose effectiveness due to other Candida species and resistance. New medications are thus required. Secreted aspartic protease of C. parapsilosis (Sapp1p) is a promising target. We have thus solved the crystal structures of Sapp1p complexed to four peptidomimetic inhibitors. Three potent inhibitors (Ki: 0.1, 0.4, 6.6 nM) resembled pepstatin A (Ki: 0.3 nM), a general aspartic protease inhibitor, in terms of their interactions with Sapp1p. However, the weaker inhibitor (Ki: 14.6 nM) formed fewer nonpolar contacts with Sapp1p, similarly to the smaller HIV protease inhibitor ritonavir (Ki: 1.9 µM), which, moreover, formed fewer H-bonds. The analyses have revealed the structural determinants of the subnanomolar inhibition of C. parapsilosis aspartic protease. Because of the high similarity between Saps from different Candida species, these results can further be used for the design of potent and specific Sap inhibitor-based antimycotic drugs.

Keywords: Inhibitor; crystal structure; hydrogen bonds; noncovalent interactions; peptidomimetics.

MeSH terms

  • Aspartic Acid Endopeptidases / antagonists & inhibitors*
  • Aspartic Acid Endopeptidases / metabolism
  • Candida parapsilosis / enzymology*
  • Dose-Response Relationship, Drug
  • Fungal Proteins / antagonists & inhibitors*
  • Fungal Proteins / metabolism
  • Models, Molecular
  • Molecular Structure
  • Peptidomimetics / chemical synthesis
  • Peptidomimetics / chemistry
  • Peptidomimetics / pharmacology*
  • Protease Inhibitors / chemical synthesis
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology*
  • Structure-Activity Relationship

Substances

  • Fungal Proteins
  • Peptidomimetics
  • Protease Inhibitors
  • Aspartic Acid Endopeptidases
  • SAPP1 protein, Candida parapsilosis

Grants and funding

ML, JD and IP were supported by the project ‘Chemical Biology for Drugging Undruggable Targets’ [ChemBioDrug CZ.02.1.01/0.0/0.0/16_019/0000729] from the European Regional Development Fund (OP RDE). JD, JB, IP, OH and ML were supported by the institutional project RVO 61388963 and LV by the project RVO 86652036. ML was supported by the Ministry of Education, Youth and Sports of the Czech Republic from the Large Infrastructures for Research, Experimental Development, and Innovations project ‘IT4 Innovations National Supercomputing Center – LM2015070’.